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Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers 
to breast and ovarian cancers. Two new studies reveal that FANCD2, a 
key component of the Fanconi anemia pathway, is essential for the 
survival of cells with BRCA1/2 mutations. These findings pave the way 
for new “synthetic lethal” strategies to kill BRCA-mutated cancers.   
 
Individuals with heterozygous mutations in the BRCA1 or BRCA2 tumor 
suppressor genes have a greatly increased risk of developing breast and 
ovarian cancers. Together, BRCA1 and BRCA2 mutations are responsible for 
up to 25% of hereditary breast cancers1, and there is an urgent need for 
developing strategies to improve treatment of these cancers. In this light, two 
recent studies2,3 have demonstrated that cells with mutations in BRCA1/2 
cannot tolerate loss of components of the Fanconi anemia (FA) pathway of 
genome maintenance. Both studies reveal that the high levels of DNA 
replication stress known to occur in cells with BRCA1/2 mutations4 is 
counteracted by the FA pathway. Loss of FANCD2, a key component of the 
FA pathway, from BRCA1/2-mutated cells causes levels of replication stress 
to soar out of control thereby triggering replication fork catastrophe and cell 
death (Fig. 1). FANCD2 becomes ubiquitinated in response to replication 
stress, in a manner catalyzed by an E3 ubiquitin ligase comprising a group of 
eight FA “core complex” proteins5. Ubiquitination of FANCD2 is known to be 
required for cell tolerance of perturbations during DNA replication6,7 and, 
accordingly, it is also essential for the survival of BRCA1/2-mutated cells3. 
Both BRCA1 and BRCA2 are important for a mode of DNA repair known as 
homologous recombination (HR), which repairs and resets stressed and 
broken DNA replication forks4. BRCA1 has multiple roles in HR, while BRCA2 
acts primarily as a reservoir of the RAD51 recombinase, which it helps to 
deposit onto DNA breaks to facilitate HR8. Intriguingly, the deposition of 
RAD51 by BRCA2 has a fork-protective role that prevents replication stress in 
a way that is separate from HR9. The significance of these various fork-
protective functions of BRCA1 and BRCA2 is underscored by the high degree 
of replication stress seen in cells with mutations in these genes; the resulting 
genetic instability probably explains why defective BRCA1/2 function causes 
cancer.  
 
Like mutations in FANCD2, some mutations in BRCA1 and BRCA2 can cause 
FA, which is characterized by bone marrow failure, developmental defects 
and predisposition to a range of cancers 10,11. The FA pathway is responsible 
for facilitating repair of DNA inter-strand crosslinks (ICLs), which block 
replisome progression5. It is also essential for protecting replication forks from 
the replication stress caused by ICLs or in other circumstances12. The 
observations that mutations in FANCD2, BRCA1 or BRCA2 can cause FA 
suggested these genes are in some respects equivalent in function. However, 
the recent studies from the Tarsounas, D’Andrea and Ceccaldi labs show that 
this is not always the case, as FANCD2 acquires a vital role in cells with 
BRCA1/2 mutations2. Precisely how FANCD2, and its ubiquitination by the FA 
core complex, prevents the replication stress seen in BRCA-mutated cells 
from rising to deadly levels is not entirely clear. However, Tarsounas and 
colleagues provide important clues. They show that FANCD2 limits damage to 
replication forks possibly by helping to arrest and then re-start forks that stall 
and/or collapse in BRCA-mutated cells (Fig. 1). Further work is needed to 
understand how FANCD2 enables these protective responses. D’Andrea, 
Ceccaldi and colleagues provide further clues by presenting evidence that the 
“synthetic lethality” resulting from loss of FANCD2 ubiquitination in cells with 
mutations in BRCA1/2 may reflect an unanticipated role for FANCD2 in 
promoting a mode of DNA repair termed “alternative end-joining” (alt-EJ)3. 
Consistent with this view, it was previously shown that loss of a specialized 
DNA polymerase - POLθ - which promotes alt-EJ is synthetic lethal in cells 
with BRCA1/2 mutations13,14. The implication from these data is that collapsed 
forks, which cannot be repaired because HR is not functional in cells with 
defects in BRCA1/2, can be rescued by alt-EJ. D’Andrea, Ceccaldi and 
colleagues now show that POLθ is recruited to stalled forks in a manner 
dependent on FANCD2 ubiquitination, and that FANCD2-depleted cells show 
a reduced capacity for alt-EJ3. These data are consistent with an essential 
role for alt-EJ, facilitated by ubiquitin-FANCD2, in cells with BRCA1/2 
mutations. It is interesting to note that besides POLθ two other proteins are 
known to be recruited to stalled forks by ubiquitin-FANCD2, and may 
therefore contribute to protecting BRCA-defective cells. These are the HR-
promoting factor CTIP15, and the FAN116,17 nuclease, which is known to work 
closely with ubiquitin-FANCD2 in protecting stalled replication forks. CTIP loss 
does not kill BRCA-mutated cells3, but the effect of FAN1 loss has yet to be 
examined, and this will be an important area of investigation.  
 
Synthetic lethality provides a conceptual framework for the development of 
drugs that are selectively toxic in specific genetic backgrounds associated 
with human disease. A classic example is the toxicity of PARP (poly-ADP 
ribose polymerase) inhibitors in cells with BRCA1/2 mutations. PARP is 
involved in repairing single-strand breaks (SSB); inhibiting PARP causes the 
accumulation of SSBs which, if they persist into S-phase, can cause fork 
collapse. As the repair of collapsed forks requires HR, PARP inhibitors cannot 
be tolerated in BRCA-mutated cells18. PARP inhibitors have shown promise in 
clinical trials but a major limitation in their use in treating cancers is intrinsic 
and acquired resistance, and so there is a great need for alternatives19. The 
two new studies suggest that inhibiting FANCD2 function might represent a 
novel strategy for the treatment of BRCA-deficient cancers (Fig. 2). This 
notion is strongly supported by the exciting observation that FANCD2 
depletion impaired the growth of tumors derived from breast cancer cells 
xenotransplanted into mice3. From a clinical perspective, how might FANCD2 
function be inhibited in BRCA1/2-mutated cancers? FANCD2 is not an 
enzyme and so drugging it may not be possible but preventing its 
ubiquitination by inhibiting the E3 ligase activity of the FA core complex might 
be a way to selectively kill BRCA-mutated tumors. Alternatively, interfering 
with enzymes that act downstream of ubiquitin-FANCD2 may be an option. An 
obvious candidate is POLθ, which is recruited to stressed forks by ubiquitin-
FANCD23: the synthetic lethality resulting from loss of POLθ in BRCA-mutated 
cells has already catapulted this enzyme to the forefront of anti-cancer drug 
discovery13,14 (Fig. 2). FAN1 is also recruited to stalled forks by ubiquitin-
FANCD217 and if, like FANCD2, FAN1 turns out to be required to counteract 
the high levels of fork stress in BRCA-mutated cells then small molecule 
FAN1 inhibitors may also be selectively toxic in BRCA-mutated tumors (Fig. 
2). These considerations provide new hope for the development of novel 
treatments for breast and ovarian cancers caused by BRCA1 and BRCA2 
mutations. It is worth considering that heightened replication stress is not 
unique to cancers caused by BRCA mutations. Indeed, switching on a range 
of oncogenes causes replication stress20,21 and thus pathways that limit 
replication stress in BRCA-mutated cancers may also be vital for the survival 
of other cancers.  
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Figure Legends: 
Figure 1: FancD2 protects replication forks and prevents cell death in 
BRCA1/2 deficient cancers. Mutations in BRCA1/2 genes lead to high levels 
of DNA replication stress and genetic instability. By protecting stressed 
replication forks from catastrophe, FancD2 prevents cell death in BRCA1/2 
deficient cancers. 
Figure 2: Strategy to selectively target BRCA1/2-deficient cancers by 
inhibiting FancD2 function. In response to replication stress, FancD2 is 
ubiquitinated by the FA core complex (E3 ligase), and this in turn promotes 
replication fork protection. in order to regulate downstream factors such as 
Poθ (polymerase) and Fan1 (nuclease). Therefore inhibiting the activity of the 
FA core complex, which would prevent FANCD2 ubiquitination, should be 
toxic in BRCA1/2-mutated cancers. Alternatively, inhibiting enzymes 
downstream of ubiquitin-FANCD2 such as POLθ or FAN1 may be toxic in 
these cancers. In this light, it has already been shown that BRCA-mutated 
cells cannot tolerate loss of POLθ13,14 but FAN1 has not yet been 
investigated. 
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